Herriott James, Exact Sciences SVP, sells $90k in EXAS stock

James Herriott, SVP, General Counsel & Secretary at Exact Sciences Corp (NASDAQ:EXAS), sold 1,500 shares of the company’s common stock on October 9, 2024, at a price of $60.00, for a total transaction value of $90,000.

Following the transaction, Herriott directly owns 14,085 shares of Exact Sciences Corp. He also indirectly owns 1,556 shares held in a 401(k) plan. With analyst price targets ranging from $53 to $85, InvestingPro subscribers can access 8 additional key insights about EXAS’s valuation and growth prospects through the comprehensive Pro Research Report.

The transaction was executed under a Rule 10b5-1 trading plan adopted on March 3, 2025.

In addition to the reported shares, Herriott holds 37,434 vested and unvested options and restricted stock units.

In other recent news, Exact Sciences reported several noteworthy developments. The company has launched Cancerguard, a multi-cancer early detection blood test, in the United States. This test can detect more than 50 types of cancer and is available as a laboratory-developed test priced at $689. Additionally, a new study published in the Journal of the National Cancer Institute highlights the efficiency of Exact Sciences’ Cologuard Plus for colorectal cancer screening. On the financial front, Piper Sandler raised its price target for Exact Sciences to $70, citing growth potential in the Cologuard franchise and expanding opportunities in Cancerguard and Minimal Residual Disease testing. Benchmark also increased its price target to $60, aligning with its 2026 EV/Revenue estimate. Meanwhile, BTIG adjusted its price target to $60 following Exact Sciences’ recent deal with Freenome, which was described as surprising by the analyst. These developments indicate significant activity and interest in Exact Sciences’ testing capabilities and market potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.